港股早評:中美會談取得實質性進展,三大指數大幅高開,科技股、蘋果概念股強勢
中美達成重要共識,會談取得實質性進展。港股三大指數大幅高開,恆指漲1.38%,國指漲1.45%,恆生科技指數漲2.15%。盤面上,大型科技股集體上漲,其中,美團、京東漲近3%,快手、阿里巴巴漲超2%,騰訊、百度漲近2%,小米飄紅;前期受關稅影響走低的蘋果概念股集體走強,高偉電子漲超6%,瑞聲科技、比亞迪電子、舜宇光學漲4%;機器人概念股、汽車股、特斯拉概念股、濠賭股、海運股、軟件類股、內險股、光伏股等齊漲。另一方面,現貨黃金跌2%短暫下破3260美元,黃金股全線下跌,赤峯黃金跌近5%,生物醫藥股跌幅明顯,樂普醫療跌超11%,諾誠健華、亞盛醫藥跌超7%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.